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The potential use of stem cells as therapeutics in disease has gained momentum over the last few years and recently phase-I clinical
trials have shown favourable results in treatment of a small cohort of acute stroke patients. Similarly, they have been used in
preclinicalmodels drug-loaded for the effective treatment of solid tumours.Herewe have characterized uptake and release of a novel
p5-cyclin-dependent kinase 5 (CDK5) inhibitory peptide by mesenchymal stem cells and showed release levels capable of blocking
aberrant cyclin-dependent kinase 5 (CDK5) signaling pathways, through phosphorylation of cyclin-dependent kinase 5 (CDK5)
and p53. These pathways represent the major acute mechanism stimulating apoptosis after stroke and hence its modulation could
benefit patient recovery. This work indicates a potential use for drug-loaded stem cells as delivery vehicles for stroke therapeutics
and in addition as anticancer receptacles particularly, if a targeting and/or holding mechanism can be defined.
1. Introduction
Despite all recent advances in ischemic stroke research, treat-
ments and recovery rates of patients have not been improved
significantly [1]. Such a clinical scenario underscores the
importance of investing in new therapeutic approaches.
The preclinical and clinical studies have shown that stem
cell-based therapies have the enormous potential for the
treatment of awide range of diseases [2]. Adult stem cells have
been studied extensively and are already a successful source of
FDA-approved treatments for a number of diseases including
juvenile diabetes and Parkinson’s disease. In contrast to
the treatment of diseases such as diabetes and Parkinson’s
disease where restricted populations are lost, multiple cell
types are lost in stroke and it will be important to repair
both blood vessels (endothelial cells, smooth muscle cells,
and pericytes) and neurons and glial cells [3–5]. Another
important distinction is that stroke is an acute injury limited
in time, which might make the brain more hospitable to
transplantation than in other diseases. Mesenchymal stem
cells (MSCs, also called mesenchymal stromal cells) have the
advantage of being relatively easy to propagate in vitro and
implantation of autologousMSCs into patients has fewer eth-
ical problems and is not subject to alloimmunization and thus
may represent an ideal candidate for cellular therapies [6].
Cyclin-dependent kinase 5 (CDK5), a serine/threonine
kinase, in complex with its activators, p35 (protein of
35 kDa) and p39 (protein of 39 kDa), is essential for early
neurodevelopment in mammals [1]. However, a variety of
neurotoxic conditions, such as ischemic brain damage, oxida-
tive stress, amyloid 𝛽 peptide (A𝛽), excitotoxicity, calcium
dyshomeostasis, and inflammation, induce influx of calcium
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ions and a rise in the intracellular Ca2+, thereby promoting
activation of calpain, a Ca2+-activated protease, which in
turn cleaves p35 into p25 and a p10 fragment [7, 8]. p25
forms a more stable CDK5-p25 hyperactive complex, which
causes aberrant hyperphosphorylation of various substrates
of CDK5 like Tau and neurofilament, leads to neuronal
apoptosis, and is associated with neuropathology. Therefore,
a therapeutic approach directed specifically at CDK5-p25
complex might prove successful. However, kinase inhibitors
(such as roscovitine) are not very specific as they inhibit not
only CDK5-p25 but also CDK5-p35 and other CDKs, leading
to serious side effects and thereby reducing the therapeutic
efficacy. In order to overcome this problem, several peptides
consisting of amino acid residues of p35, such as CDK5
inhibitory peptide (CIP, a peptide of 125 amino acid residues),
p10, and p5 have been generated and proven to specifically
reduce CDK5-p25 increased activity without affecting the
normal endogenous CDK5-p35 or other CDKs activities [9–
15]. In particular, p5 also reduced neuronal apoptosis induced
by hypoxia/ischemia brain injury, high glucose-mediated
toxicity, or A𝛽 stress [12–14]. Based on these encouraging
findings, we decided to investigate whether MSCs could
uptake and release p5 peptide and then inhibit CDK5 acti-
vation induced by calpain in endothelial cells as well as the
potential of MSCs as drug carrier to deliver p5 to the peri-
infarcted regions and protect endothelial cells and neurons
against CDK5-p25 induced toxicity in these regions.
2. Materials and Methods
2.1. Cell Culture. Human adipose-derivedmesenchymal stem
cells (hADMSCs) were kindly provided by Professor Giulio
Alessandri and Professor Valentina Cocce. HAD-MSCs were
isolated from periumbilical fat tissue and characterized as
described [16]. Cells were grown in stem cellsmedium (SCM)
comprised of 80% Iscove’s modified Dulbecco’s medium
(IMDM; Sigma-Aldrich) containing 5% fetal bovine serum
(FBS; Sigma-Aldrich), 10% NeuroCult medium (Stem Cell
Technologies), and 10% endothelial basal medium (EBM)
(Lonza) in a humidified incubator with 5% CO
2
at 37∘C.
Bovine aortic endothelial cells (BAECs) were cultured in
Dulbecco’s Modified Eagles Medium (DMEM; Lonza) sup-
plemented with 10% FBS.
2.2. p5 Priming of hADMSCs. p5, a 24-residue peptide,
derived fromp35, theCDK5 activator, was chemically synthe-
sized and the single biotin moiety was conjugated on the N-
terminus [15] (21st Century Biochemicals). The sequence of
p5-biotin peptide is Biot-Ahx-KEAFWDRCLSVINLMSSK-
MLQINA-OH. The toxicity of p5 on hADMSCs was deter-
mined in a 24-hour alamarBlue assay (cytotoxicity test; Life
Technologies) and in a 3-day alamarBlue assay (antiprolifera-
tive test). Based on these results, the p5 priming of hADMSCs
was carried out with three doubling concentrations, 3, 6,
and 12 𝜇g/mL. Briefly, subconfluent cultures (2 × 105) of
hADMSCs were exposed to different dosages of p5. After 24-
hour of incubation, the cells were washed twice with PBS and
trypsinized. Cells were then seeded in a new flask in fresh
SCM. After 24-hour of culture, the cell conditioned medium
(CM) was collected and tested for protective effects in vitro
onBAECs. CM fromuntreated hADMSCs cultured under the
same conditions was used as control.
2.3. Immunofluorescence Analysis. 2 × 104 hADMSCs plated
on glass coverslips in 24-well multiwell plates in SCM
were grown to subconfluence over 24 hours. The cells were
then treated with 3 𝜇g/mL p5. At the end of the specified
incubation period (1, 2, 4, 8, or 24 hours), the cells were
fixed in 4% paraformaldehyde. For other time points, the cell
media containing p5 were removed after 24-hour incubation,
and cells were washed 3 times in PBS and fed with fresh SCM.
At the corresponding time point, the cells were fixed in 4%
paraformaldehyde.
BAECs (1 × 104) plated on glass coverslips in 24-well
multiwell plates in DMEMwere grown to subconfluence over
24 hours.The cells were treated with different concentrations
of p5 or CMof p5-primed hADMSCs for 24 hours. Cells were
fixed in 4% paraformaldehyde.
p5 was detected using anti-fluorescein (biotin) antibody
(Abcam) 1 : 200 in milk. Coverslips were then mounted
using Vectashield mounting medium with DAPI (Vector
Laboratories) and sealed with nail varnish. Images were
obtained at 200x magnification using Imager Z1 fluorescence
microscope (Zeiss) and fluorescence intensity was quantified
by ImageJ 1.49 software (https://imagej.nih.gov/). Presented
values are averages of six images.
2.4. Western Blot Analysis. 7 × 104 BAECs plated in 6-well
multiwell plates in DMEMwere grown to subconfluence over
24 hours.The cells were treated with 5𝜇Mcalcium ionophore
A23187 (Sigma-Aldrich) and 2.5mM CaCl
2
(Sigma-Aldrich)
with or without p5 or CM of p5-primed hADMSCs. The
cells were lysed in RIPA buffer containing protease inhibitor
cocktail and phosphatase inhibitor cocktail (Sigma-Aldrich).
Western blot was performed using 10% SDS-PAGEwith 40𝜇g
total proteins. The proteins were transferred to polyvinyli-
dene difluoride (PVDF) membrane. The membrane was
blocked in a blocking solution (pH 7.4) composed of 1%
BSA (Sigma-Aldrich) dissolved in TBS containing 0.1%
Tween-20 (TBS-Tween, pH 7.4) for 1 hour and incubated
with the primary antibodies including anti-phospho-CDK5
(pTyr15) (Sigma-Aldrich, 1 : 500), anti-CDK5 (Cell Signal-
ing Technology, 1 : 1,000), anti-p35 (Abcam, 1 : 100), anti-
phospho-ERK1/2 (Cell Signaling Technology, 1 : 2,000), anti-
ERK1/2 (Cell Signaling Technology, 1 : 1,000), anti-phospho-
p53 (pSer15) (Cell Signaling Technology, 1 : 500), anti-
p53 (Sigma-Aldrich, 1 : 500), anti-active caspase-3 (Sigma-
Aldrich, 1 : 200), anti-procaspase-3 (Abcam, 1 : 250), and anti-
𝛼-tubulin (Abcam, 1 : 5,000). The horseradish peroxidase
(HRP) conjugated secondary antibodies, goat anti-rabbit IgG
or goat anti-mouse IgG (Daco), were used. The immunore-
activity was visualized with chemiluminescence detection kit
(Pierce ECL Western Blotting Substrate; Thermo Scientific).
Western blot images were captured with Chemidoc Touch
Imaging system (Bio-Rad). Molecular weights of proteins
were estimated by comparison with MagicMark XP western
Stem Cells International 3
protein standard (Invitrogen). Blots shown are one of at least
two independent experiments performed.
2.5. LC-MS Analysis. Liquid chromatography-mass spec-
trometry (LC-MS) analysis was performed using an Agilent
1290 LC system coupled to an Agilent 6530 high defini-
tion quadrupole time-of-flight (q-TOF) mass spectrometer,
equipped with an Agilent Jet Stream technology dual elec-
trospray source. The p5 peptides were prepared in methanol
(OPTIMA LC-MS grade; Fisher Scientific) and chromato-
graphic separation was performed on Waters Symmetry C18
column (2.1 × 50mm i.d., 3.5 𝜇m; Agilent Technologies). The
column was eluted at a flow rate of 0.5mL/minutes using
water as mobile phase A and acetonitrile as mobile phase B,
both containing 0.1% formic acid. 0.1% of mobile phase B was
kept constant and then a linear gradient was started to reach
100%mobile phase B in 15minutes and held until 20minutes;
then gradient is set to reach 50% B in 25 minutes and then
held till 40 minutes; final gradient is set to reach 0.1% B in 55
minutes and then held at 0.1% B till 60 minutes. The column
temperature was maintained at 20∘C and injection volume
was 10 𝜇L.
The column effluent was directly introduced into the
electrospray source of q-TOF mass spectrometer. Analyses
were performed in the positive ion mode with scan range
of 100–3200𝑚/𝑧 and scan rate of 1 spectra per second.
The electrospray source conditions were as follows: capillary
2000V, nozzle 500V, fragmentor 80V, skimmer 45V, drying
gas 80∘C at 8 L/minutes, nebulisation gas 15 psig, and sheath
gas 350∘C at 10 L/minutes. Agilent Mass Hunter software was
used to acquire and process the data (acquisition version
B.05.00 and qualitative data analysis version B.05.00).
2.6. In Vitro Proliferative Assay. The protective effect of
both p5 or CM of p5 primed hADMSCs on BAECs pro-
liferation after the treatment of Ca2+ ionophore combined
with CaCl
2
was determined by the alamarBlue assay (Life
Technologies). Briefly, 1.2 × 103 BAECs were plated in 96-
well multiwell plates in DMEM. The cells were then treated
with 5𝜇M calcium ionophore A23187 (Sigma-Aldrich) and
2.5mM CaCl
2
(Sigma-Aldrich) with or without p5 or CM
of p5-primed hADMSCs. Three wells were devoted for the
assay every day for 3 days, and time-course of cell prolif-
eration was monitored. In practice, 10 𝜇L of the alamarBlue
reagent (Life Technologies) was added to each well and the
plates were incubated at 37∘C for 4 hours in a humidified
atmosphere with 5% CO
2
before recording fluorescence
(530Ex/590Em) using a SynergyHTmultidetectionmicroplate
reader (BioTek Instruments). According to the standard
curve for BAECs generated from fluorescence signals plotted
against the number of cells (between 0 and 2.0 × 104 BAECs),
cell numbers were calculated from the fluorescence signals.
3. Results
3.1. Uptake and Release of p5 by hADMSCs. p5 is a 24-residue
peptide derived from p35, the CDK5 activator. Since p5 is the
basic peptide and needs acetic acid to be fully dissolved, we
tested the toxicity of the p5 solution on both hADMSCs and
BAECs. The maximum dose of p5, which will not affect cell
viability and proliferation, was 12 𝜇g/mL using alamarBlue
assay. Based on these results, three doubling concentrations,
3, 6, and 12 𝜇g/mL, were employed in the current study.
Subconfluent culture (2× 104) of adherent hADMSCswas
exposed to 3 𝜇g/mL biotinylated p5.The internalization of p5
into hADMSCs was investigated by fluorescence microscopy
using anti-fluorescein (biotin) antibody over time. After 1
hour of priming, the internalization of p5 by hADMSCs was
appreciable (Figures 1(a) and 1(d)).The stainingwas gradually
intensified and enriched in cytoplasm at the end of priming
(24 hours). After 24 hours, the distribution of p5 remained in
cytoplasm for 5 days whereas the staining decreased from day
10, suggesting its possible excretion, degradation, or both.
To assess if p5-primed hADMSCs could release p5 into
themedia, subconfluent culture (2 × 105) of adherent hADM-
SCs was exposed to 12 𝜇g/mL biotinylated p5 for 24 hours.
After several washes and trypsinization, p5-primed hADM-
SCs were further cultured and their conditioned medium
(CM) was collected every 24 hours and tested on BAECs.
There was evident p5 staining in BAECs treated with CM of
p5-primed hADMSCs collected on Days 1 and 2, the staining
decreased onDay 3, and no stainingwas observed fromDay 4
onwards, suggesting that p5-primed hADMSCs continuously
released p5 into medium for 3 days, with the peak release
within the first 48 hours (Figures 1(c) and 1(f)). Comparing
the p5 staining intensity in BAECs treated with pure p5 and
CM, we estimated that the p5 in the CM collected on Days 1
and 2 was equivalent to 212.60 ± 31.89 ng/mL and 178.41 ±
24.98 ng/mL, respectively, and the p5 in the CM collected on
Day 3 was equivalent to 116.50 ± 13.98 ng/mL (Figures 1(b),
1(c), 1(e), and 1(f)).
3.2. LC-MS Analysis of p5. In order to quantify the p5
release by p5-primed hADMSCs, we tested p5 by LC-MS
analysis. LC-MS analysis can detect p5 and the measured ion
1046.1700𝑚/𝑧 corresponding to [M]3+ that is in excellent
agreement with the expected value (Figure 2). The average
peak area for 200 ng/mL p5 from 6 tests was 5563.63 counts
and 2430.55 counts for 100 ng/mL p5 (Figures 2(b) and 1(c)).
The ESI-MS spectra showed no peak for 50 ng/mL p5. The
results indicated that LC-MS analysis can quantitate p5,
which was found to be linear between 100 and 200 ng/mL
among the range of released p5 by p5-primed hADMSCs
within the first 3 days estimated by immunofluorescence
assay (Figures 1(c) and 1(f)), but undetectable at 50 ng/mL.
LC-MS analysis will be used for the quantification of the p5
release by p5-primed hADMSCs in the future work.
3.3. The Activation of CDK5 by Calpain in Cultured Endothe-
lial Cells. A previous study had showed that Ca2+ ionophore
alone and in combination with CaCl
2
activated endogenous
calpain, thereby activating CDK5 by the cleavage of p35 to
p25 in the cultured neurons [7]. We investigated whether
combined treatment of Ca2+ ionophore and CaCl
2
is able
to activate and phosphorylate CDK5 through calpain in cul-
tured endothelial cells. The western blotting results showed
4 Stem Cells International
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Figure 1: The p5 internalization and release by hADMSCs. (a) The internalization of p5 was analyzed by fluorescence microscopy in
hADMSCs primed 1, 2, 4, 8, or 24 hours with 3𝜇g/mL p5 (green). Cells were also observed after 24 hours priming onDays 2, 3, 4, 5, 10, and 14.
(b) The internalization of p5 was analyzed by fluorescence microscopy in BAECs primed with different doses of p5 (green) for 24 hours. The
intensity of p5 staining in cytoplasm was correlated with the dosages of p5. (c) Subconfluent cultures (2 × 105) of adherent hADMSCs were
exposed to 12𝜇g/mL biotinylated p5 for 24 hours. After several washes and trypsinization, p5-primed hADMSCs were further cultured and
their conditioned medium (CM) was collected every 24 hours. The internalization of p5 was analyzed by fluorescence microscopy in BAECs
treated with p5-primed hADMSCs CM for 24 hours. Scale bar: 100𝜇m. (d)The fluorescein staining intensities of p5 in hADMSCs in (a) were
quantified in the bar graph as means ± SD (error bars). Significance (denoted as ∗) was calculated compared to the untreated control group
using Student’s 𝑡-test (with 𝑝 < 0.01, 𝑛 = 6). (e) The fluorescein staining intensities of p5 in BAECs in (b) were quantified in the bar graph as
means ± SD (error bars). (f) The fluorescein staining intensities of p5 in BAECs in (c) were quantified in the bar graph as means ± SD (error
bars). Significance (denoted as ∗) was calculated compared to the untreated control group using Student’s 𝑡-test (with 𝑝 < 0.01, 𝑛 = 6).
that the levels of p35 decreased whereas the phosphorylation
levels of CDK5 increased after 10 and 15 minutes of treatment
of Ca2+ ionophore and CaCl
2
; thereafter p35 levels increased
and pCDK5 levels decreased immediately, suggesting that
Ca2+ ionophore and CaCl
2
treatment activated endogenous
calpain and transiently cleaved p35 into p25, which in turn
activated and phosphorylated CDK5 in endothelial cells
(Figure 3).
Because calpain was reported to be activated during
apoptotic cell death, we suspected a link between the
activation of CDK5 and cell death [1, 17]. Indeed, the
Ca2+ ionophore and CaCl
2
treatment induced cell death
in endothelial cells as early as 10 minutes’ treatment; we
therefore checked the MAPK signaling pathway and genes
involved in apoptosis [1]. The phosphorylation levels of
ERK1/2 showed the similar pattern as pCDK5 whereas
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Figure 2: LC/MS with Q-TOF analysis of p5. (a) The total ion chromatogram (TIC) of 200 ng/mL p5. (b) Positive ESI mass spectra
(1046.1700𝑚/𝑧 corresponding to [M]3+ in excellent agreement with the expected value) of 20.70 ± 0.05minutes of 200 ng/mL p5.The area of
peak was circled. The average peak area for 200 ng/mL p5 from 6 tests was 5563.63 counts. (c) Positive ESI mass spectra (1046.1700𝑚/𝑧) of
20.70 ± 0.05minutes of 100 ng/mL p5. The area of peak was circled. The average peak area for 100 ng/mL p5 from 6 tests was 2430.55 counts.
The ESI-MS spectra showed no peak for 50 ng/mL p5 (data not shown).
phospho-p53 expression increased gradually following the 10
minutes’ treatment of Ca2+ ionophore and CaCl
2
(Figure 3).
For phospho-p53 blots, preabsorption needs to be under-
taken to ensure validity of its identification since there are two
bands close together. In contrast, caspase-3 was activated at 4
hours of treatment, much later than p53 (Figure 3).
3.4. p5-Primed hADMSCs Released p5 and Inhibited CDK5
Activation by Calpain in Cultured Endothelial Cells. We
investigated whether p5 could inhibit the activation of CDK5
induced by calpain. Comparedwith the 10minutes’ treatment
of Ca2+ ionophore and CaCl
2
alone, all the three concentra-
tions of p5 (3, 6, and 12 𝜇g/mL) suppressed the cleavage of p35
and phosphorylation of CDK5 induced by Ca2+ ionophore
and CaCl
2
. The highest and the least inhibition was caused
by 6 𝜇g/mL and 12 𝜇g/mL, respectively (Figure 4(a), lanes 4–
7). More interestingly, 3 𝜇g/mL p5 prevented the activation
of p53 by Ca2+ ionophore and CaCl
2
, suggesting p5 might
protect cells from apoptosis by inhibiting p53. The less
effectiveness of higher dosages of p5, especially 12𝜇g/mL,
might be due to the relative higher concentration of acetic
acid in these p5 solutions. Surprisingly, pERK1/2 levels were
not affected by p5 treatment, indicating that ERK1/2 was
activated in endothelial cells by Ca2+ ionophore and CaCl
2
treatment independently of CDK5 signaling.
We then investigated whether hADMSCs primed with
p5 would release p5 in the sufficient amount to inhibit
the p35 cleavage and CDK5 activation induced by calpain.
The hADMSCs were exposed to three dosages of p5 (3, 6,
and 12 𝜇g/mL) for 24 hours. Based on the time-course of
p5 release by immunofluorescence assay (Figures 1(c) and
1(f)), conditionedmedium (CM) from p5-primed hADMSCs
collected on Day 1 was tested on BAECs. The CM from
12 𝜇g/mL p5-primed hADMSCs inhibited the cleavage of
p35 and the CDK5 phosphorylation and more importantly
suppressed phospho-p53 expression after Ca2+ ionophore
and CaCl
2
treatment (Figure 4(a), lane 10). Similarly to
p5 alone, CM of p5-primed hADMSCs did not affect the
phosphorylation of ERK1/2 induced by Ca2+ ionophore and
CaCl
2
treatment.
3.5. p5-Primed hADMSCs Protected Endothelial Cells from
Calpain-Induced Toxicity. As the Ca2+ ionophore and CaCl
2
treatment activated apoptosis related genes, such as p53
and caspase-3, we further examined the cytotoxic effects
of the combined treatment of Ca2+ ionophore and CaCl
2
towards BAECs. Compared to the untreated cells, the 10
minutes’ treatment of Ca2+ ionophore andCaCl
2
significantly
inhibited BAECs proliferation by 60.9% (𝑝 < 0.01) whereas
2 hours’ treatment inhibited BAECs growth by 90.5% (𝑝 <
0.01) in a 24-hour alamarBlue assay. We then investigated
whether p5 or p5-primed hADMSCs would protect BACEs
against the cytotoxicity induced by Ca2+ ionophore and
CaCl
2
treatment. Two concentrations of p5 (3 and 6 𝜇g/mL)
and conditioned medium (CM) from 12 𝜇g/mL p5-primed
hADMSCs collected on Day 1 were tested on BAECs. The
proliferation assays showed that p5 and CM of p5-primed
hADMSCs did not affect the BAECs numbers with the 10
minutes’ treatment of Ca2+ ionophore and CaCl
2
through
3 days (Figure 5(a)). However, compared with the 2 hours’
treatment of Ca2+ ionophore and CaCl
2
alone, the BAECs
numbers in 6𝜇g/mL p5 group increased by 13% on Day 2,
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Figure 3: The activation of CDK5 by calpain in cultured BAECs. (a) The cultured BAECs were treated with 5 𝜇M calcium ionophore A23187
and 2.5mM CaCl
2
for 0, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, or 4 hours. At the end of the treatment, the cells were collected,
suspended in SDS-PAGE sample buffer, and boiled for 5 minutes. Each sample was run on a 10% SDS-PAGE gel and blotted with anti-p35,
anti-phospho-CDK5 (pTyr15), anti-phospho-ERK1/2, anti-phospho-p53 (pSer15), anti-active caspase-3, anti-CDK5, anti-ERK1/2, anti-p53,
anti-procaspase-3, and anti-tubulin antibodies. The first lane was loaded with the extract from untreated BAECs as control. The cultured
BAECs treated with 10 ng/mL FGF2 for 10 minutes were used as positive control for the phosphorylation of ERK1/2 (lane 8). Blots shown
are one of at least three independent experiments performed. (b) Densitometric analysis of immunoblots quantification. Data are means ±
SD (error bars). Significance (denoted as ∗) was calculated compared to the untreated control (lane 1) using Student’s 𝑡-test (with 𝑝 < 0.05,
𝑛 = 3).
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Figure 4: p5 and CM from p5-primed hADMSCs inhibited CDK5 and p53 activation by calpain in cultured BAECs. (a)The cultured BAECs
were treated with p5 (lanes 5–7) or conditionedmedium (CM) from p5-primed hADMSCs collected onDay 1 (lanes 8–10) for 1 hour and then
further treated with 5 𝜇M calcium ionophore A23187 and 2.5mM CaCl
2
for 10 minutes. The 3 𝜇g/mL p5 treatment alone (lane 1), CM from
untreated hADMSCs (lane 2) and untreated BAECs (lane 3) were used as control. The p35 cleavage and the phosphorylation of CDK5 and
p53 were suppressed by p5 and CM from p5-primed hADMSCs. (b) Densitometric analysis of immunoblots quantification. Data are means
± SD (error bars). Significance (denoted as ∗) was calculated compared to cells treated with 5 𝜇M calcium ionophore A23187 and 2.5mM
CaCl
2
(lane 4) using Student’s 𝑡-test (with 𝑝 < 0.05).
20% on Day 3, and 22% on Day 4 although these increases
were not statistically significant (Figure 5(b)). More encour-
agingly, the BAECs numbers in p5-primed hADMSCs CM
group increased by 35% on Day 2, 43% on Day 3 (𝑝 <
0.05), and 26% on Day 4 (𝑝 < 0.05) compared with the 2
hours’ treatment of Ca2+ ionophore and CaCl
2
alone (Fig-
ure 5(b)).The coculture of p5-primed hADMSCs and BAECs
warrants the further evaluation of the p5-primed hADMSCs
protection against BAECs cytotoxicity induced by the calpain
activation.
4. Discussion
In the present study, our results demonstrated that, by simply
incubating hADMSCs with p5, hADMSCs can uptake p5
and release biologically functional p5 in a time-dependent
kinetics as well as in the dosage sufficient to inhibit the
cleavage of p35, the phosphorylation of CDK5, and the
upregulation of p53 induced by the activation of calpain
in endothelial cells. As such, p5-loaded hADMSCs might
be employed to protect endothelial cells from CDK5-p25
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Figure 5: p5 and conditioned medium (CM) from p5-primed hADMSCs protected BAECs from calpain-induced cytotoxicity. The cultured
BAECs were treated with p5 or CM from 12𝜇g/mL p5-primed hADMSCs collected on Day 1 for 1 hour and then further treated with 5𝜇M
calcium ionophore A23187 and 2.5mM CaCl
2
for 10 minutes (a) or 2 hours (b). The cell proliferation was monitored for 3 consecutive days
using the alamarBlue assay. Data are means ± SD (error bars). Significance (denoted as ∗) was calculated compared to the control using
Student’s 𝑡-test (with 𝑝 < 0.05, 𝑛 = 3).
hyperactivity-induced toxicity caused by the intracellular
Ca2+ rise and calpain activation under the exposure to
stress, such as hypoxia/ischemia injury, oxidative stress, and
inflammation.
The use of MSCs as an active targeted-delivery vehicle for
therapeutic agents is especially attractive because MCSs have
proven to be permissive to small compound incorporation,
immunoprotective and pathotropic. Considering the limiting
number of MSCs which can be delivered in vivo, it is impor-
tant to have enoughdrug incorporated into theMSCs in order
to achieve a therapeutic drug concentration in the targeted
tissues [18]. Numerous studies on the uptake of nanoparticles
in hADMSCs have shown that the internalization of nanopar-
ticles can be improved by modification of the nanoparticles,
size control, proper incubation time, and nanoparticle con-
centration [19]. In the current study, we aimed to load MSCs
with CDK5 inhibitory peptides, the molecules being much
bigger than nanoparticles, to inhibit the CDK5-p25 activity.
The large peptides may be problematic with regard to the
incorporation of peptides into the cells, which is controlled
by both endocytosis into and exocytosis out of the cells. We
therefore chose the smallest available truncated peptides of
p35. p5 is a 24-residue mimetic peptide of p35 C-terminal
and more readily diffusible peptide that specifically inhibits
CDK5-p25 activity but does not affect endogenous CDK5-
p35 activity [12–15]. Our work demonstrated for the first time
that, through a simple in vitro process of priming, hADMSCs
incorporated a sufficient amount of p5.
To be effective, a therapeutic agent must first be stably
loaded inside the cell carrier and then be released into the
extracellular space slowly and steadily, instead of a quick
release into the systemic circulation before the cells reach
the target site, thereby giving the cell carrier time to migrate
towards the stroke regions and reach as many target cells as
possible after the systemic delivery. Our results showed that
the uptake of p5 in hADMSCs increased in a time-dependent
manner, starting at 1-hour incubation and gradually enriched
in cytoplasm at the end of 24-hour priming. After internal-
ization, p5-primed hADMSCs continuously released p5 into
medium for 3 days, with the peak release within the first
48 hours, whereas the substantial amount of p5 remained
in cytoplasm for more than 5 days. The incorporation and
release kinetics of nanoparticles inMSCs for the treatment of
malignant glioma revealed that nanoparticles demonstrated
an initial burst release from cells within the first 4 hours
followed by a steady release over 9 days [20]. This kinetics
is particularly advantageous since priming MSCs with p5
requires at least 8 hours for the maximum loading, during
which the burst release of p5 is complete and therefore the p5
loaded in the cells are in the sustained release phase. As such,
p5 retained within the cells act as intracellular drug depots,
gradually releasing the encapsulated peptide. The timed
drug release can be further designed by the modification
of “internal” and “external” triggers. A pH-sensitive linker
releases drugs upon nanoparticle along a pH gradient [21].
Considering that the hypoxic regions usually result in a low
pH microenvironment, pH-dependent release could allow
controlled drug release only in the targeted stroke sites. Taken
together, although highly promising, a better understanding
of drug release fromMSCs may offer the new means of more
specific, selective, timed, and controlled release of drugs in
vivo.
It was also critical to ensure that drug loading did not
affect the viability of MSCs or their native properties, espe-
cially their pathotropic properties. Several studies proved that
loading anticancer-drug nanoparticles or even chemother-
apeutic drugs did not affect the short-term or long-term
viability of MSCs [19, 22]. Our work also confirmed that
neither chemotherapeutic drug paclitaxel nor p5 loading
affects the viability of MSCs (unpublished data). A property
critical to the use of MSCs as drug carriers is their migratory
potential. In vitro transwell experiments have demonstrated
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that nanoparticles loaded MSCs still possess the migration
capacity towards chemoattractant and tumour cells (e.g.,
U87MG and U251 glioma cells) [20, 23]. Similarly, our
unpublished data showed that the uptake of cytotoxic drug
doxorubicin did not impair themigratory properties ofMSCs
to lung cancer cells.
CDK5 is a serine/threonine kinase and plays pivotal
roles mostly in neuronal development and survival [1]. It is
selectively activated in neurons by its noncyclin activators
p35 and p39. The increasing evidences suggest that CDK5
becomes a cell death mediator when its activator p35 is
cleaved to p25 by calpain [7, 8]. This inappropriate activation
of CDK5 has been reported in neuronal death involved in
the pathophysiology of several neurodegenerative diseases,
including Alzheimer’s disease, amyotrophic lateral sclerosis,
Parkinson’s disease, and prion-related encephalopathies. In
addition, recent studies show that overactivation of CDK5 is
a crucially prodeath signal in stroke [1]. The accumulation
of p25 after transient forebrain ischemia activated CDK5
and induces CA1 cell death [24]. Hypoxia/ischemia injury in
neonatal rats also causedCDK5 activation and increased neu-
ronal apoptosis [12]. So far more than 20 specific substrates of
CDK5 have been identified, including a number of substrates
linked to apoptosis, such as Tau, p53, caspase-3, Bax, and Bcl-
2 [1, 25]. p5 was reported to specifically inhibit the CDK5-
p25 signaling pathway [12–14]. Furthermore, p5 reduced A𝛽-
induced Tau hyperphosphorylation and apoptosis in cortical
neurons and decreased cleaved caspase-3 levels and neuronal
apoptosis in Alzheimer’s disease mouse model and a rat
hypoxia/ischemia injury model [12–15].
In the present study, we examined whether p5 and
p5-primed MSC inhibited CDK5 activity and reduced the
markers of apoptosis induced by calpain in endothelial cells.
The western blotting results showed that Ca2+ ionophore
combined with CaCl
2
treatment increased the cleavage of
p35, the phosphorylation levels of CDK5 and ERK1/2 tran-
siently, and p53 expression gradually at 10 minutes’ treatment
whereas caspase-3 was activated at 4 hours of treatment,
much later than p53. More importantly, both p5 alone and
p5-primed hADMSCs suppressed the cleavage of p35, the
phosphorylation of CDK5, and the upregulation of p53
induced by calpain, suggesting that p5-loaded hADMSCs
may protect cells from apoptosis via inhibiting p53. p53 is a
critical modulator of cellular stress responses and is activated
through diverse mechanisms. It was reported that CDK5
interacted with p53 and increased its stability by prevent-
ing HMD2-induced p53 ubiquitylation and downregulation,
leading to accumulation of p53 in neurons [25]. CDK5 may
also facilitate the function of p53 and p73 transcriptional
complexes [26]. Whether CDK5 regulates p53 transcription-
ally, translationally, or posttranslationally in endothelial cells
needs to be further investigated. Besides, the previous studies
showed that CDK5 protected neurons from cell death by
direct interaction and activation of the antiapoptotic protein
Bcl-2 and in PC12 neuronal cells via inhibition of sustained
activation of ERK1/2 [1]. However, pERK1/2 levels were
not affected by the p5 inhibition of CDK5 in this study,
suggesting that ERK1/2 was activated in endothelial cells by
Ca2+ ionophore andCaCl
2
treatment independently of CDK5
signaling. Since the in vivo p5 inhibition studies reduced
active caspase-3 levels at 24 hours after hypoxia/ischemia
injury and 10 days in Alzheimer’s disease mice, future work
will be carried out to assess the long-term protective effects
of p5-primed hADMSCs [12, 14].
5. Conclusions
Toour knowledge, this is the first demonstration that, without
any genetic manipulation, mesenchymal stem cells can be
loaded in vitro with small bioactive peptides blocking CDK5
hyperactivity. The potential of use for p5-loaded hADMSCs
in stroke and regulation of cell growth in other diseasemodels
such as cancer needs to be explored and their therapeutic
efficacy may be further investigated in animal and human
clinical trials.
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